FY2026 EPS Forecast for Kyverna Therapeutics Cut by Analyst

Kyverna Therapeutics, Inc. (NASDAQ:KYTX – Free Report) – Stock analysts at HC Wainwright dropped their FY2026 earnings per share estimates for shares of Kyverna Therapeutics in a research note issued on Friday, November 13th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($2.71) per share for the year, down from their previous estimate of ($2.70). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($2.70) per share. HC Wainwright also issued estimates for Kyverna Therapeutics’ Q4 2027 earnings at ($0.53) EPS and FY2027 earnings at ($2.78) EPS.

Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.01.

Several other brokerages have also recently commented on KYTX. Benchmark reiterated a “buy” rating on shares of Kyverna Therapeutics in a report on Friday, September 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Monday, September 21st. William Blair upgraded shares of Kyverna Therapeutics to a “strong-buy” rating in a report on Wednesday, September 23rd. Finally, Needham & Company LLC set a $25.00 price target on shares of Kyverna Therapeutics in a research report on Friday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $29.00.

Read Our Latest Stock Report on Kyverna Therapeutics

Kyverna Therapeutics Stock Down 5.7%

Shares of KYTX opened at $4.76 on Tuesday. Kyverna Therapeutics has a 1 year low of $4.49 and a 1 year high of $13.67. The company has a debt-to-equity ratio of 0.15, a quick ratio of 9.06 and a current ratio of 9.06. The business has a 50-day moving average of $6.15 and a 200-day moving average of $7.86.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in KYTX. Bank of America Corp DE acquired a new position in Kyverna Therapeutics in the second quarter valued at approximately $2,365,000. Walleye Capital LLC bought a new position in shares of Kyverna Therapeutics during the 2nd quarter worth approximately $2,188,000. BlackRock Inc. bought a new position in shares of Kyverna Therapeutics during the 2nd quarter worth approximately $27,931,000. Renaissance Technologies LLC grew its position in shares of Kyverna Therapeutics by 106.6% during the 1st quarter. Renaissance Technologies LLC now owns 367,492 shares of the company’s stock worth $3,171,000 after buying an additional 189,593 shares during the period. Finally, AIGH Capital Management LLC acquired a new stake in shares of Kyverna Therapeutics during the 2nd quarter worth approximately $24,911,000. 18.08% of the stock is owned by institutional investors.

About Kyverna Therapeutics

(Get Free Report)

Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing cell therapies for people with autoimmune diseases. The company’s approach aims to use engineered immune cells to address disease-causing B cells. Its lead candidate, KYV-101, is an autologous CAR T-cell therapy designed to target CD19, a protein found on B cells. Kyverna is evaluating the therapy in clinical studies for several autoimmune conditions, including stiff person syndrome, myasthenia gravis and lupus nephritis.

See Also

Earnings History and Estimates for Kyverna Therapeutics (NASDAQ:KYTX)

Receive News & Ratings for Kyverna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyverna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.